의료기기 이야기

Background on eSTARThe electronic submission template and resource (eSTAR) template can be used to submit US FDA Premarket Notifications (510(k)s), De Novos, and Traditional Premarket Applications (PMAs). eSTAR was compulsory for 510(k) submissions starting in October 2023. eSTAR will be required for De Novos starting in October 2025.eSTAR version 5.5eSTAR Version 5.5 was released (February 12)...

We last wrote about the U.S. FDA eSTAR when it became compulsory for 510(k)s. At the time, the eSTAR was voluntary for De Novos. Background on De NovosThe De Novo Classification Request “De Novo” is the regulatory mechanism used when manufacturers have a novel medical device that they expect is not high risk and so should be Class II (special controls and general controls) or Class I (general co..

FDA에서 최초로 암 유형의 소인을 평가하기 위한 DNA 테스트에 대한 시판 승인을 하였다. - 업체: Invitae Corporation (미국) - 제품명: Invitae Common Hereditary Cancer Panel - 허가: FDA De Novo (DEN210011) - 제품성능: 9,000개의 임상샘플과 99% 이상의 정확도 - 검체: 혈액 - 47 genes - 검사기간: 10~21일 (보통 14일) FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types | FDA FDA Grants First Marketing Authorization for a ..